tbuckley/cabot-search huggingface dataset:
Prognostic Relevance of Dominant Blood T-Cell Clones in Early Mycosis Fungoides
Authors: Laura Gleason, Neda Nikbakht
Journal: JAMA Dermatology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Association of Concomitant Gestational Hypertensive Disorders and Gestational Diabetes With Cardiovascular Disease
Authors: Justin B. Echouffo Tcheugui, Jun Guan, Longdi Fu, Ravi Retnakaran, Baiju R. Shah
Journal: JAMA Network Open (2022)

Importance Accruing evidence suggests that gestational hypertensive disorders (GHTD) and gestational diabetes (GD) are each associated with an increased risk of cardiovascular disease (CVD). However, the extent to which the co-occurrence of GHTD and GD is associated with the risk of CVD remains largely unknown. Objective To estimate the individual and joint associations of GHTD and GD with incident CVD. Design, Setting, and Participants This population-based cohort study used the Ministry of Health and Long-Term Care of Ontario (Canada) health care administrative databases. All women in Ontario with a GHTD and/or GD diagnosis, and a live-birth singleton delivery between July 1, 2007, and March 31, 2018, were considered for inclusion. Women with pregravid diabetes, hypertension, or cardiovascular disease were excluded. Statistical analysis was performed from November 2021 to September 2022. Exposures GD and/or GHTD, defined using diagnosis coding. Main Outcomes and Measures Individual and joint associations of GHTD and GD with incident CVD (including a composite of myocardial infarction, acute coronary syndrome, stroke, coronary artery bypass grafting, percutaneous coronary intervention, or carotid endarterectomy), estimated using Cox regression models, adjusting for relevant cardiometabolic risk factors. The follow-up extended from the index pregnancy until March 31, 2020. Results Among 886 295 eligible women (mean [SD] age, 30 [5.6] years; 43 861 [4.9%] with isolated GHTD, 54 061 [6.1%] with isolated GD, and 4975 [0.6%] with GHTD and GD), there were 1999 CVD events over 12 years of follow-up. In the early postpartum phase (first 5 years post partum), there was no association of co-occurrence of GTHD and GD (adjusted hazard ratio [aHR], 1.42, 95% CI, 0.78-2.58) or GD alone (aHR, 0.80; 95% CI, 0.60-1.06) with CVD; there was an association between isolated GTHD and incident CVD compared with no GTHD and no GD (aHR, 1.90; 95% CI, 1.51-2.35). In the late postpartum period (after the initial 5 years post partum), compared with no GD and no GHTD, isolated GHTD (aHR, 1.41, 95% CI, 1.12-1.76) and co-occurrence of GHTD and GD (aHR, 2.43, 95% CI, 1.60-3.67) were each associated with a higher risk of incident CVD. There was no association between isolated GD and incident CVD. Conclusions and Relevance In this cohort study, GHTD was associated with a high risk of CVD post partum, and the co-occurrence of GD and GHTD was associated with a much greater postpartum CVD risk. These findings suggest that CVD preventive care is particularly needed in the aftermath of combined GD and GHTD.
2021 Coronary Revascularization Guidelines—Lessons in the Importance of Data Scrutiny and Reappraisal of Evidence
Authors: Faisal G. Bakaeen, Danny Chu, Victor Dayan
Journal: JAMA Surgery (2022)

This Viewpoint discusses whether or not the evidence cited in the 2021 American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography & Interventions guidelines for coronary artery revascularization support downgrading coronary artery bypass grafting relative to medical therapy.
Reducing Antibiotic Exposure at the Beginning of Life
Authors: Luregn J. Schlapbach, Enitan D. Carrol
Journal: JAMA Network Open (2022)

Eric Giannoni, MD; Varvara Dimopoulou, MD; Claus Klingenberg, MD, PhD; Lars Navér, MD, PhD; Viveka Nordberg, MD, PhD; Alberto Berardi, MD; Salhab el Helou, MD; Gerhard Fusch, PhD; Joseph M. Bliss, MD, PhD; Dirk Lehnick, PhD; Nicholas Guerina, MD, PhD; Joanna Seliga-Siwecka, MD, PhD; Pierre Maton, MD; Donatienne Lagae, MD; Judit Mari, MD, PhD; Jan Janota, MD, PhD; Philipp K. A. Agyeman, MD; Riccardo Pfister, MD, PhD; Giuseppe Latorre, MD; Gianfranco Maffei, MD; Nicola Laforgia, MD; Enikő Mózes, MD; Ketil Størdal, MD, PhD; Tobias Strunk, MD, PhD; Martin Stocker, MD; AENEAS Study Group; Maria Grazia Capretti ; Martina Ceccoli; Morena De Angelis; Pietro Drimaco; Khalyane Eap; Zoe el Helou; Rana Esmaeilizand; Alessandra Foglianese; Carmelo Geraci; Bartłomiej Grochowski; Stellan Håkansson; Sharandeep Kaur; Anne-Louise Kollegger; Frida Oldendorff; Vittoria Rizzo; Arild E. Rønnestad; Damber Shrestha; Hans Jørgen Stensvold; Anaïs Torregrossa; Martin Trefny; Kristyna Zilinska; Aleksandra Zwijacz
Paying Attention to Attention-Deficit/Hyperactivity Disorder Medications and Cardiovascular Risk
Authors: Roy C. Ziegelstein
Journal: JAMA Network Open (2022)

Le Zhang, MPH; Honghui Yao, MSc; Lin Li, PhD; Ebba Du Rietz, PhD; Pontus Andell, MD, PhD; Miguel Garcia-Argibay, PhD; Brian M. D’Onofrio, PhD; Samuele Cortese, MD, PhD; Henrik Larsson, PhD; Zheng Chang, PhD
Targeting Chemoprophylaxis in Venous Thromboembolism Using Biomarker Guidance
Authors: Michael H. Cutrone, Ian J. Welsby, Kamrouz Ghadimi
Journal: JAMA Surgery (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Use of Acupuncture for Adult Health Conditions, 2013 to 2021
Authors: Jennifer Allen, Selene S. Mak, Meron Begashaw, Jody Larkin, Isomi Miake-Lye, Jessica Beroes-Severin, Juli Olson, Paul G. Shekelle
Journal: JAMA Network Open (2022)

Acupuncture is a popular treatment that has been advocated for dozens of adult health conditions and has a vast evidence base.To map the systematic reviews, conclusions, and certainty or quality of evidence for outcomes of acupuncture as a treatment for adult health conditions.Computerized search of PubMed and 4 other databases from 2013 to 2021. Systematic reviews of acupuncture (whole body, auricular, or electroacupuncture) for adult health conditions that formally rated the certainty, quality, or strength of evidence for conclusions. Studies of acupressure, fire acupuncture, laser acupuncture, or traditional Chinese medicine without mention of acupuncture were excluded. Health condition, number of included studies, type of acupuncture, type of comparison group, conclusions, and certainty or quality of evidence. Reviews with at least 1 conclusion rated as high-certainty evidence, reviews with at least 1 conclusion rated as moderate-certainty evidence, and reviews with all conclusions rated as low- or very low-certainty evidence; full list of all conclusions and certainty of evidence.A total of 434 systematic reviews of acupuncture for adult health conditions were found; of these, 127 reviews used a formal method to rate certainty or quality of evidence of their conclusions, and 82 reviews were mapped, covering 56 health conditions. Across these, there were 4 conclusions that were rated as high-certainty evidence, and 31 conclusions that were rated as moderate-certainty evidence. All remaining conclusions (>60) were rated as low- or very low-certainty evidence. Approximately 10% of conclusions rated as high or moderate-certainty were that acupuncture was no better than the comparator treatment, and approximately 75% of high- or moderate-certainty evidence conclusions were about acupuncture compared with a sham or no treatment.Despite a vast number of randomized trials, systematic reviews of acupuncture for adult health conditions have rated only a minority of conclusions as high- or moderate-certainty evidence, and most of these were about comparisons with sham treatment or had conclusions of no benefit of acupuncture. Conclusions with moderate or high-certainty evidence that acupuncture is superior to other active therapies were rare.
Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder
Authors: Le Zhang, Honghui Yao, Lin Li, Ebba Du Rietz, Pontus Andell, Miguel Garcia-Argibay, Brian M. D’Onofrio, Samuele Cortese, Henrik Larsson, Zheng Chang
Journal: JAMA Network Open (2022)

Importance Use of attention-deficit/hyperactivity disorder (ADHD) medications has increased substantially over the past decades, but there are concerns regarding their cardiovascular safety. Objective To provide an updated synthesis of evidence on whether ADHD medications are associated with the risk of a broad range of cardiovascular diseases (CVDs). Data Sources PubMed, Embase, PsycINFO, and Web of Science up to May 1, 2022. Study Selection Observational studies investigating the association between ADHD medications (including stimulants and nonstimulants) and risk of CVD. Data Extraction and Synthesis Independent reviewers extracted data and assessed study quality using the Good Research for Comparative Effectiveness (GRACE) checklist. Data were pooled using random-effects models. This study is reported according to the Meta-analyses of Observational Studies in Epidemiology guideline. Main Outcomes and Measures The outcome was any type of cardiovascular event, including hypertension, ischemic heart disease, cerebrovascular disease, heart failure, venous thromboembolism, tachyarrhythmias, and cardiac arrest. Results Nineteen studies (with 3 931 532 participants including children, adolescents, and adults; 60.9% male), of which 14 were cohort studies, from 6 countries or regions were included in the meta-analysis. Median follow-up time ranged from 0.25 to 9.5 years (median, 1.5 years). Pooled adjusted relative risk (RR) did not show a statistically significant association between ADHD medication use and any CVD among children and adolescents (RR, 1.18; 95% CI, 0.91-1.53), young or middle-aged adults (RR, 1.04; 95% CI, 0.43-2.48), or older adults (RR, 1.59; 95% CI, 0.62-4.05). No significant associations for stimulants (RR, 1.24; 95% CI, 0.84-1.83) or nonstimulants (RR, 1.22; 95% CI, 0.25-5.97) were observed. For specific cardiovascular outcomes, no statistically significant association was found in relation to cardiac arrest or arrhythmias (RR, 1.60; 95% CI, 0.94-2.72), cerebrovascular diseases (RR, 0.91; 95% CI, 0.72-1.15), or myocardial infarction (RR, 1.06; 95% CI, 0.68-1.65). There was no associations with any CVD in female patients (RR, 1.88; 95% CI, 0.43-8.24) and in those with preexisting CVD (RR, 1.31; 95% CI, 0.80-2.16). Heterogeneity between studies was high and significant except for the analysis on cerebrovascular diseases. Conclusions and Relevance This meta-analysis suggests no statistically significant association between ADHD medications and the risk of CVD across age groups, although a modest risk increase could not be ruled out, especially for the risk of cardiac arrest or tachyarrhythmias. Further investigation is warranted for the cardiovascular risk in female patients and patients with preexisting CVD as well as long-term risks associated with ADHD medication use.
Statin-Associated Muscle Symptoms Among New Statin Users Randomly Assigned to Vitamin D or Placebo
Authors: Mark A. Hlatky, Pedro Engel Gonzalez, JoAnn E. Manson, Julie E. Buring, I-Min Lee, Nancy R. Cook, Samia Mora, Vadim Bubes, Neil J. Stone
Journal: JAMA Cardiology (2022)

Statin-associated muscle symptoms (SAMS) are common and may lead to discontinuation of indicated statin therapy. Observational studies suggest that vitamin D therapy is associated with reduced statin intolerance, but no randomized studies have been reported.To test whether vitamin D supplementation was associated with prevention of SAMS and a reduction of statin discontinuation.Men 50 years or older and women 55 years or older, free of cancer and cardiovascular disease, were enrolled in a randomized, placebo-controlled, double-blind clinical trial of vitamin D supplementation. Participants who initiated statin therapy after randomization were surveyed in early 2016. The data were analyzed in early 2022.Daily cholecalciferol (2000 international units) or placebo with assessment of statin prescriptions during follow-up.Muscle pain or discomfort lasting several days (primary outcome) and discontinuation of a statin due to SAMS (secondary outcome).Statins were initiated by 1033 vitamin D-assigned participants and 1050 placebo-assigned participants; mean (SD) age was 66.8 (6.2) years and 49% were women. Over 4.8 years of follow-up, SAMS were reported by 317 participants (31%) assigned vitamin D and 325 assigned placebo (31%). The adjusted odds ratio (OR) was 0.97 (95% CI, 0.80-1.18; P = .78). Statins were discontinued by 137 participants (13%) assigned to vitamin D and 133 assigned to placebo (13%) with an adjusted OR of 1.04 (95% CI, 0.80-1.35; P = .78). These results were consistent across pretreatment 25-hydroxy vitamin D levels (interaction P value = .83). Among participants with levels less than 20 ng/mL, SAMS were reported by 28 of 85 vitamin D-assigned participants (33%) and 33 of 95 placebo-assigned participants (35%). For those with levels less than 30 ng/ml, SAMS were reported by 88 of 330 vitamin-D assigned participants (27%) and 96 of 323 of placebo-assigned participants (30%).Vitamin D supplementation did not prevent SAMS or reduce statin discontinuation. These results were consistent across pretreatment 25-hydroxy vitamin D levels.ClinicalTrials.gov Identifier: NCT01169259.
Progressive Hair Loss With Short Hair in a Child
Authors: Chia-Lun Li, Chih-Chiang Chen
Journal: JAMA Dermatology (2022)

A school-aged girl presented to the dermatology clinic with a 6-year history of hair loss and short hair, and light microscopy of scalp hair shafts revealed no structural abnormalities, such as cuticular damage, twisting, bending, or miniaturization. What is your diagnosis?
External Validation of the Skin and UV Neoplasia Transplant Risk Assessment Calculator (SUNTRAC) in a Large European Solid Organ Transplant Recipient Cohort
Authors: Álvaro Gómez-Tomás, Jan Nico Bouwes Bavinck, Roel Genders, Carlos González-Cruz, Estella de Jong, Sarah Arron, Vicente García-Patos, Carla Ferrándiz-Pulido
Journal: JAMA Dermatology (2022)

The Skin and UV Neoplasia Transplant Risk Assessment Calculator (SUNTRAC) tool has been developed in the US to facilitate the identification of solid organ transplant recipients (SOTRs) at a higher risk of developing skin cancer. However, it has not yet been validated in populations other than the one used for its creation.To provide an external validation of the SUNTRAC tool in different SOTR populations.This retrospective external validation prognostic study used data from a prospectively collected cohort of European SOTRs from transplant centers at teaching hospitals in the Netherlands (1995-2016) and Spain (2011-2021). Participants were screened and followed up at dermatology departments. Data were analyzed from September to October 2021.The discrimination ability of the SUNTRAC tool was assessed via a competing risk survival analysis, cumulative incidence plots, and Wolbers concordance index. Calibration of the SUNTRAC tool was assessed through comparison of projected skin cancer incidences. Skin cancer diagnoses included squamous cell carcinoma, basal cell carcinoma, melanoma, and Merkel cell carcinoma.A total of 3421 SOTRs (median age at transplant, 53 [quartile 1: 42; quartile 3: 62] years; 2132 [62.3%] men) were assessed, including 72 Asian patients (2.1%), 137 Black patients (4.0%), 275 Latinx patients (8.0%), 109 Middle Eastern and North African patients (3.2%), and 2828 White patients (82.7%). With a total of 23 213 years of follow-up time, 603 patients developed skin cancer. The SUNTRAC tool classified patients into 4 groups with significantly different risks of developing skin cancer during follow-up. Overall, the relative rate for developing skin cancer estimated using subdistribution hazard ratios (SHRs) and using the low-risk group as the reference group, increased according to the proposed risk group (medium-risk group: SHR, 6.8 [95% CI, 3.8-12.1]; P < .001; high-risk group: SHR, 15.9 [95% CI, 8.9-28.4]; P < .001; very-high-risk group: SHR, 54.8 [95% CI, 29.1-102.9]; P < .001), with a concordance index of 0.72. Actual skin cancer incidences were similar to those predicted by the SUNTRAC tool (5-year skin cancer cumulative incidence for medium-risk group: predicted, 6.2%; observed, 7.0%).The findings of this external validation prognostic study support the use of the SUNTRAC tool in European populations for stratifying SOTRs based on their skin cancer risk and also detecting patients at a high risk of developing skin cancer. This can be helpful in prioritizing and providing better screening and surveillance for these patients.
Skin and UV Neoplasia Transplant Risk Assessment Calculator (SUNTRAC)—Keeping Solid Organ Transplant Recipients on Track for Skin Cancer Screening
Authors: Priscilla L. Kojder, Anokhi Jambusaria-Pahlajani
Journal: JAMA Dermatology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Errors in Figure 1
Journal: JAMA Oncology (2022)

Thierry Conroy, MD; Florence Castan, MSc; Anthony Lopez, MD; Anthony Turpin, MD, PhD; Meher Ben Abdelghani, MD; Alice C. Wei, MD, CM; Emmanuel Mitry, MD, PhD; James J. Biagi, MD; Ludovic Evesque, MD; Pascal Artru, MD; Thierry Lecomte, MD, PhD; Eric Assenat, MD, PhD; Lucile Bauguion, MD; Marc Ychou, MD, PhD; Olivier Bouché, MD, PhD; Laure Monard, PharmD; Aurélien Lambert, MD; Pascal Hammel, MD, PhD; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group; Eric Francois; Jean-François Ramee; Hélène Castanie; Marc Pracht; François Ghiringhelli; Emmanuel Maillard; Caroline Couffon; Julien Volet; Vincent Bourgeois; Marion Chauvenet; Jean-Frédéric Blanc; Denis Péré-Vergé; Christelle De La Fouchardiere; Antoine Adenis; Farid El Hajbi; Jaafar Bennouna; Patrick Texereau; Roger Faroux; Laurent Miglianico; Christian Platini; Jean-Louis Legoux; François-Xavier Caroli-Bosc; Karine Bouhier-Leporrier; Alice Gagnaire; Victoire Granger; Valérie Lebrun-Ly; Rosine Guimbaud; Yann Touchefeu; Mohamed Gasmi; Frédéric Di Fiore; Jean François Seitz; Pierre-Luc Etienne; Catherine Ligeza Poisson; Yves Rinaldi; Nabil Baba-Hamed; Jean Baptiste Bachet; Thomas Aparicio; Laurence Chone; Marielle Guillet; Julien Forestier; Eric Terrebonne; Mohamed Hebbar; Gilles Breysacher; Thierry Andre; Faiza Khemissa-Akouz; Vincent Hautefeuille; Véronique Guerin-Meyer; Johannes Hartwig; Yves Becouarn; David Malka; Christophe Louvet; Jean-Luc Raoul; Laurent Cany; Beata Juzina; Claire Jouffroy; Sophie Gourgou; Mohammad Rassouli; Haji Chalchal; Daniel Renouf; Ralph Wong; Frederic Lemay; Francine Aubin ; Felix Couture; Elaine Mc Whirter; Stephen Welch; Petr Kavan; Brian Findlay; Christine Cripps; Pablo Cano; Shahid Ahmed; Mohammed Harb; Bryn Pressnail; Scott Dowden; Chris O'Callaghan
Targeting Chemoprophylaxis in Venous Thromboembolism Using Biomarker Guidance—Reply
Authors: Bryan A. Cotton, Jessica C. Cardenas
Journal: JAMA Surgery (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Safety and Efficacy of Robotic vs Open Liver Resection for Hepatocellular Carcinoma
Authors: Fabrizio Di Benedetto, Paolo Magistri, Stefano Di Sandro, Carlo Sposito, Christian Oberkofler, Ellie Brandon, Benjamin Samstein, Cristiano Guidetti, Alexandros Papageorgiou, Samuele Frassoni, Vincenzo Bagnardi, Pierre-Alain Clavien, Davide Citterio, Tomoaki Kato, Henrik Petrowsky, Karim J. Halazun, Vincenzo Mazzaferro, Barbara Catellani, Gian Piero Guerrini, Jorgelina Coppa, Maria Flores
Journal: JAMA Surgery (2022)

Long-term oncologic outcomes of robotic surgery remain a hotly debated topic in surgical oncology, but sparse data have been published thus far.